Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.77 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.56 |
| ▸ | PPARG | P37231 | 5/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.54 |
| ▸ | ACP1 | P24666 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2542491 | 0.87 | PIM1 (1.00) | PIM1NLRP3ENPP2PTPN1ACP1 | |
| SCHEMBL2542488 | 0.87 | PIM1 (1.00) | PIM1NLRP3ENPP2PTPN1ACP1 | |
| SCHEMBL2542486 | 0.87 | PIM1 (1.00) | PIM1NLRP3ENPP2PTPN1ACP1 | |
| SCHEMBL12237195 | 0.86 | PPARG (0.65) | PIM1NLRP3ENPP2PPARGPTPN1 | |
| SCHEMBL6689684 | 0.85 | ENPP2 (0.68) | PIM1ENPP2PPARGPTPN1ACP1 | |
| SCHEMBL6689682 | 0.85 | ENPP2 (0.68) | PIM1ENPP2PPARGPTPN1ACP1 | |
| SCHEMBL6688929 | 0.85 | PPARG (0.67) | PIM1ENPP2PPARGPTPN1ACP1 | |
| SCHEMBL6688926 | 0.85 | PPARG (0.67) | PIM1ENPP2PPARGPTPN1ACP1 | |
| SCHEMBL6692178 | 0.83 | PPARG (0.58) | PIM1ENPP2PPARGPTPN1ACP1 | |
| SCHEMBL6686984 | 0.83 | PPARG (0.58) | PIM1ENPP2PPARGPTPN1ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263664-A1 | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer | PIM1, PIM2, PIM3 | PIM1 1/4885NLRP3 4566/4885ENPP2 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.